Nurix therapeutics to participate in upcoming investor conferences

San francisco, aug. 31, 2023 (globe newswire) -- nurix therapeutics, inc. (nasdaq: nrix), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that arthur t. sands, m.d., ph.d., nurix's president and chief executive officer will participate in the following conferences in september:
NRIX Ratings Summary
NRIX Quant Ranking